Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VCAM1 | P19320 | 1/20 | 0.40 |
| ▸ | CDK1 | P06493 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 2/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | CA9 | Q16790 | 2/20 | 0.36 |
| ▸ | CA5A | P35218 | 1/20 | 0.36 |
| ▸ | ABL1 | P00519 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9079062 | 0.88 | VCAM1 (0.40) | VCAM1CDK1CA1CA2CA9 | |
| SCHEMBL19494504 | 0.87 | CDK1 (0.38) | CDK1CA1CA2CA9CA5A | |
| SCHEMBL4278676 | 0.82 | VCAM1 (0.40) | VCAM1CDK1CA1CA2CA9 | |
| SCHEMBL4279013 | 0.82 | VCAM1 (0.40) | VCAM1CDK1CA1CA2CA9 | |
| SCHEMBL4267413 | 0.81 | CA2 (0.42) | VCAM1CDK1CA1CA2CA9 | |
| SCHEMBL9448542 | 0.80 | VCAM1 (0.40) | VCAM1CDK1CA1CA2CA9 | |
| SCHEMBL16825561 | 0.80 | CCR2 (0.41) | VCAM1CA1CA2CA9CA5A | |
| SCHEMBL8132556 | 0.78 | MAPT (0.41) | VCAM1CDK1CA1CA2CA9 | |
| SCHEMBL9658540 | 0.78 | SLC6A3 (0.35) | VCAM1ALDH1A1 | |
| SCHEMBL8489410 | 0.76 | VCAM1 (0.40) | VCAM1CDK1CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3235799-B1 | OXIME COMPOUND AND HERBICIDE | NISSAN CHEMICAL CORP (JP) | 2022-02-23 | — | — | EP | disclosed |
| US-11000033-B2 | Ketone or oxime compound, and herbicide | NISSAN CHEMICAL CORPORATION (JP) | 2021-05-11 | — | — | US | disclosed |
| US-20190053488-A1 | KETONE OR OXIME COMPOUND, AND HERBICIDE | NISSAN CHEMICAL CORPORATION (JP) | 2019-02-21 | — | — | US | disclosed |
| US-20170347647-A1 | KETONE OR OXIME COMPOUND, AND HERBICIDE | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2017-12-07 | — | — | US | disclosed |
| US-20170347647-A1 | KETONE OR OXIME COMPOUND, AND HERBICIDE | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2017-12-07 | — | — | US | disclosed |
| WO-2016098899-A1 | KETONE OR OXIME COMPOUND, AND HERBICIDE | 日産化学工業株式会社 | 2016-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11000033-B2 | Ketone or oxime compound, and herbicide | OR10J3, CYP1B1, CBR3 | VCAM1 4647/4885CDK1 1525/4885CA1 787/4885 |
| US-20190053488-A1 | KETONE OR OXIME COMPOUND, AND HERBICIDE | OR10J3, CYP1B1, CBR3 | VCAM1 4647/4885CDK1 1499/4885CA1 783/4885 |
| US-20170347647-A1 | KETONE OR OXIME COMPOUND, AND HERBICIDE | OR10J3, CYP1B1, CBR3 | VCAM1 4647/4885CDK1 1499/4885CA1 783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.